Hematopoietic Cell Transplantation for Multiple Myeloma

Aetna covers autologous hematopoietic cell transplantation (HCT) for amyloidosis, multiple myeloma (MM), and POEMS when the transplanting institution’s written eligibility criteria are met (or when institutional selection criteria are satisfied), allows a second autologous HCT for relapse after a durable remission, limits tandem transplants to planned first and second within 6 months, and restricts allogeneic HCT (outside a protocol) to early relapse (<24 months) after prior autologous HCT with adequate organ function. Exclusions/requirements: candidates must not have significant comorbidities, must have adequate major organ function, and are excluded if they have indolent/smoldering myeloma or MGUS, have had >1 year of alkylator-based chemotherapy, or radiation to >10% of marrow-producing bones.

"Autologous hematopoietic cell transplantation (HCT) for treatment of amyloidosis when the transplanting institution's written eligibility criteria are met."